Bibliography
- Grinsztejn B, Nguyen BY, Katlama C, Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369(9569):1261-9
- Markowitz M, Nguyen BY, Gotuzzo E, Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52(3):350-6
- Briz V, Leon-Leal JA, Palladino C, Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 2012;31(3):273-7
- Rockstroh J, Teppler H, Zhao J, Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012;13(2):127-31
- Eron JJ Jr, Rockstroh JK, Reynes J, Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase III non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
- Marinello J, Marchand C, Mott BT, Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47(36):9345-54
- Hare S, Gupta SS, Valkov E, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464(7286):232-6
- Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012;11(1):25-36
- Metifiot M, Maddali K, Naumova A, Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 2010;49(17):3715-22
- Metifiot M, Vandegraaff N, Maddali K, Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. Aids 2011;25(9):1175-8
- Molina JM, Lamarca A, Andrade-Villanueva J, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase III, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
- van Lunzen J, Maggiolo F, Arribas JR, Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase IIb trial. Lancet Infect Dis 2012;12(2):111-18
- Johnson BC, Metifiot M, Pommier Y, Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother 2012;56(1):411-19
- Hare S, Smith SJ, Metifiot M, Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011;80(4):565-72
- Cohen C, Elion R, Ruane P, Randomized, phase II evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25(6):F7-12
- Healthcare V. Shionogi-ViiV Healthcare Starts Phase III Trial for “572-Trii” Fixed-Dose Combination HIV Therapy. 2011. Available from: http://www.viivhealthcare.com/en/media-room/press-releases/2011-02-03.aspx